Skip to main content

Viking Therapeutics

Viking Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company utilizes its proprietary research platform to develop therapeutic candidates addressing indications such as non-alcoholic steatohepatitis (NASH), lipid metabolism disorders, and endocrine-driven obesity, featuring leading clinical candidates like VK2809 and VK2735. Its core operations encompass preclinical pharmacology, molecular engineering, and clinical trial advancement. As a clinical-stage development firm, the company generates minimal commercial revenue and relies on equity financing and capital markets to fund its ongoing drug development pipeline. Viking Therapeutics holds an emerging position in metabolic disease therapeutics. The company is headquartered in San Diego, California, United States, and its common stock trades on the Nasdaq Global Select Market.

5 of the funds FundTelligence covers report a position in Viking Therapeutics.

Legal name
Viking Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
5
Exposure themes
Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health

Funds holding Viking Therapeutics

Loading...